Is molecular adsorbent recirculating system effective for all the liver failure patients?

Jul 08, 2009

Since its introduction in 1993, molecular adsorbent recirculating system (MARS) albumin dialysis has been a subject of research, with the hope of treating effectively patients with acute liver failure. The impact of MARS treatment on outcome as well as clinical and laboratory variables has been investigated widely in small non-randomized studies. However, larger studies with longer follow-up time are required to determine the true usefulness of MARS treatment in different liver failure etiologies.

An article to be published on June 28 2009 in the World Journal of Gastroenterology addressed this issue. The research led by Taru Kantola from Helsinki University Central Hospital, Finland discussed the prognostic factors for survival in patients with acute . The authors analysed the 1-year outcomes of 188 patients treated with MARS from 2001 to 2007, in an specializing in liver diseases.

They found that the etiology of liver failure was the most important predictor of survival. In acute liver failure (ALF) of toxic etiology (e.g., paracetamol), the grade of encephalopathy before MARS treatment was a significant prognostic factor. In ALF of unknown etiology, coagulation factor 5 and liver enzyme alanine aminotransferase levels were prognostic. According to the results, the MARS treatment of a cirrhotic patient with an acute-on-chronic liver failure is not meaningful in terms of prognosis if the patient is not eligible for transplantation.

More information: Kantola T, Koivusalo AM, Parmanen S, Höckerstedt K, Isoniemi H. Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol 2009; 15(24): 3015-3024. www.wjgnet.com/1007-9327/15/3015.asp

Source: (news : web)

Explore further: Dermatologists present seven referral tips for rheumatologists

add to favorites email to friend print save as pdf

Related Stories

If metastasectomy should be performed before other treatments

Oct 31, 2008

Primary HCC is a major cancer related to HBV viral infection in Asian countries, including Japan. Recently, the primary liver cancers are successfully treated by surgical resection including liver transplantation and non-surgical ...

Artificial liver may extend lives

Jun 02, 2009

The first artificial organ for liver patients that uses immortalized human liver cells, the Extracorporeal Liver Assist Device, or ELAD®, is a bedside system that treats blood plasma, metabolizing toxins and synthesizing ...

Recommended for you

UN chief: Ebola cases in Mali a 'deep concern'

2 hours ago

The United Nations chief warned Friday that Ebola may be easing in part of West Africa but is still hitting hard in other areas and outpacing the international response.

Ebola death toll rises to 5,459: WHO

8 hours ago

The World Health Organization said Friday that 5,459 people had so far died of Ebola out of a total 15,351 cases of infection in eight countries since late December 2013.

Flu season off to a slow start ... for now

11 hours ago

(HealthDay)—This year's flu season is off to a slow but detectable start. And it appears to be a typical one that's likely to peak in January or February, a leading U.S. health official says.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.